Table 3.
Results of the base case rhEGF compared to conventional therapy.
| Outcomes | Amputations | QALYs | Total Cost |
|---|---|---|---|
| Without discount | |||
| rhEGF 75 μg | 0.31 | 3.98 | $19.024 |
| Conventional therapy | 0.7 | 3.32 | $ 11.346 |
| Incremental (per patient) | |||
| rhEGF 75 μg | 0.39 | 0.65 | $7.678,61 |
| Conventional therapy | |||
| With discount | |||
| rhEGF 75 μg | 0.24 | 3.51 | $18.953,73 |
| Conventional therapy | 0.56 | 2.93 | $11.164,95 |
| Discounted Incremental (per patient) | |||
| rhEGF 75 μg | |||
| Conventional therapy | 0.32 | 0.58 | $7.789 |
rhEGF: recombinant human epidermal growth factor intra- or perilesional.
Source: Chart developed with the model results.